Nasdaq auph.

Aurinia Pharmaceuticals (NASDAQ:AUPH) recently released its Q4, 2017 results, as well as, provided an update on its pipeline.The company is continuing to progress well with its Phase III AURORA ...msn.com - August 8 at 2:56 PM. Jump Financial LLC Takes $366,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) marketbeat.com - August 8 at 5:21 AM. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to Post Q1 2024 Earnings of ($0.14) Per Share, Leerink Partnrs Forecasts. marketbeat.com - August 7 at 7:47 AM.Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc ...Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares stood at 0.69 million during the latest session, with the company’s beta value hitting 1.28. At the last check today, the stock’s price was $9.28, to imply an increase of 2.66% or $0.24 in intraday trading.

Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 5% in regular trading as two board members, including the chairman, resigned from the board after receiving less than majority support in a shareholder ...

Perusahaan melaporkan laba per saham sebesar $-0,09 dan pendapatan sebesar $40,8M. Survei EPS dari analis Investing.com diharapkan sesuai perkiraan yang dirilis sebesar $-0,17 dengan laba $38,44M. Untuk tahun ini, saham Aurinia Pharma naik 65%, unggul kuat Nasdaq yang naik 24% dalam setahun hingga hari ini.Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.

What happened. Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price ...And Aurinia Pharmaceuticals Inc (Symbol: AUPH) saw options trading volume of 18,237 contracts, representing approximately 1.8 million underlying shares or approximately 88.5% of AUPH's average ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...Aurinia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUPH) $8.60 -0.09 (-1.04%) (As of 11/29/2023 ET) Compare Today's Range $8.54 $8.99 50-Day …SVB Leerink waxed optimistic on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), saying the stock could rally 250% if late-stage trial data for the company's kidney inflammation treatment shows a ...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.Amounts are expressed in U.S. dollars. Net product revenue was $40.8 million for the three months ended …

Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9.80, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Rhumbline Advisers raised its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 3.2% in the 2nd quarter, according to the company in its most recent ...Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy recommendation. Analyst Price Forecast Suggests 72.67% Upside ...AUPH Earnings Date and Information. Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company …Dec 4, 2023 · AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ... AUPH: Get the latest Aurinia Pharmaceuticals stock price and detailed information including AUPH news, historical charts and realtime prices. Indices Commodities Currencies StocksJan 5, 2023 · Aurinia Pharmaceuticals (NASDAQ:AUPH) recently announced they have reached a settlement with Sun Pharmaceuticals (OTCPK:SMPQY) to dismiss their claims and counterclaims against each other. Aurinia Pharmaceuticals AUPH shares ended the last trading session 5.7% higher at $9.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...AUPH Earnings Date and Information. Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company …About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Total cost of sales and operating expenses for the quarter ended September 30, 2023 was $70.8 million and $65.3 million for the quarter ended September 30, 2022. Total cost of sales and operating ...EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...

AUPH Latest After Hours Trades. Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 19:59:23. $9.37. 100. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission ...

Dec 4, 2023 · December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ... Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% UpsideDecember 4, 2023. Business. B. Riley Financial Inc (NASDAQ:RILY) has a beta value of 1.57 and has seen 0.91 million shares traded in the recent trading session. The company, currently valued at $723.52M, closed the recent trade at $23.66 per share which meant it gained $3.51 on the day or 17.42% during that session.AUPH Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $14.20 with a high forecast of $15.00 and a low forecast of $13.00. The average price target represents a 71.29% change from the last price of $8.29.Jun 16, 2023 · Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a good speculative biotech play to look into. That's because it already has received FDA approval of LUPKYNIS™ as an oral treatment for adult ...

What happened. Shares of the autoimmune specialist Aurinia Pharmaceuticals ( AUPH 2.09%) rose by as much as 13.2% in early morning trading Friday. The biotech's shares cooled off after their hot ...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ...

Dec 4, 2023 · The OCUL stock price is -140.48% off its 52-week high price of $7.96 and 39.58% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 808.59K shares. The consensus among analysts is that Ocular Therapeutix Inc (OCUL ... Aurinia Pharmaceuticals Inc's (NASDAQ:AUPH) ... Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) is scheduled to host a virtual event on Tuesday, Jan. 26, from 8 a.m. to 10 a.m. to provide an update on ...Financials. AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of ...Nov 27, 2023 · Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ... Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ. Aurinia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUPH) $8.60 -0.09 (-1.04%) (As of 11/29/2023 ET) Compare Today's Range $8.54 $8.99 50-Day …In a recent SEC filing, Russell Investments Group Ltd. revealed that it had added to its portfolio with a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP). The biotechnology company has become an attractive option for investors due to their focus on developing and commercializing therapies for diseases with unmet …Aurinia Pharmaceuticals ( NASDAQ: AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...Nov 24, 2023 · Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares stood at 0.69 million during the latest session, with the company’s beta value hitting 1.28. At the last check today, the stock’s price was $9.28, to imply an increase of 2.66% or $0.24 in intraday trading.

SVB Leerink waxed optimistic on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), saying the stock could rally 250% if late-stage trial data for the company's kidney inflammation treatment shows a ...Oct 28, 2020 · AUPH closed Tuesday's trading at $16.05, up 4.09%. ... views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Find the latest news headlines from Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.Instagram:https://instagram. nvda stock historyhome loans for single mothersfanduel pickleballarrived vs fundrise Below is a chart showing AUPH's trailing twelve month trading history, with the $9 strike highlighted in orange: Phillips 66 (Symbol: PSX) options are showing a volume of 21,547 contracts thus far ...Aurinia Pharmaceuticals Price Performance Shares of NASDAQ:AUPH opened at $9.06 on Monday. Aurinia Pharmaceuticals Inc. has a twelve month low of … ninja trader vsreal estate investing with 10k Aurinia Pharmaceuticals (NASDAQ: AUPH) will report its Q2 2021 earnings after the closing bell today and investors will want to pay attention to sales and any color management provides on its ...Dec 4, 2023 · December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session. kingsoft cloud stock Cramer would be careful about Aurinia Pharmaceuticals Ord Shs (NASDAQ:AUPH). Sorrento Therapeutics Inc (NASDAQ:SRNE) is overvalued, said Cramer. He is a seller.NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (2.09%) $0.18. Current Price. ... (AUPH 2.09%) rose by as much as 13.2% in early morning trading Friday. The biotech's shares ...